衞信康(603676.SH):2021年度淨利預增50%-75%
格隆匯1月20日丨衞信康(603676.SH)披露2021年度業績預增公吿,預計2021年度實現歸屬於上市公司股東的淨利潤與上年同期相比,將增加2921.24萬元-4381.86萬元,同比增加50%-75%;預計2021年度實現歸屬於上市公司股東的扣除非經常性損益後淨利潤與上年同期相比,將增加3554.92萬元-4542.40萬元,同比增加90%-115%。
報吿期內,公司核心產品注射用多種維生素(12)業務規模擴大,且公司新產品小兒多種維生素注射液(13)、多種微量元素注射液等產品逐漸放量,由此帶來公司業績的增長。公司在銷售渠道上不斷深耕細作,核心產品已沉澱並形成一定的行業優勢地位和市場影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.